The long-term goals ofthe Hematopoietic Development &Malignancy Program (HDMP) are to elucidate basic mechanisms regulating normal and malignant hematopoiesis and to use this information to develop strategies for the prevention, diagnosis, prognostic stratification, and treatment of hematopoietic malignancies. We have identified areas of institutional strength and developed the following specific translational goals of the HDMP: 1) to leverage local expertise in cancer genomics to identify novel recurrent mutations in hematopoietic malignancies and develop their translational potential;2) to expand translational research in multiple myeloma and lymphoma;3) to take advantage of local expertise in fundamental hematopoiesis research to expand translational research in bone marrow failure syndromes;4) to utilize local expertise in fundamental immunology and stem cell biology research to expand translational research in stem cell transplantation. Working groups in leukemia, lymphoma &myeloma, bone marrow failure and transplantation biology have been established to develop, review, prioritize and conduct translational research. The HDMP will foster collaborative translational research and provide training of junior investigators through research seminars, journal clubs, work-in-progress meetings and the annual HDMP retreat. The HDMP has 29 members from four Departments and one School. The HDMP is supported by $11,684,316 in funding, of which $4,798,898 is NCI funding and $6,264,597 is other peer reviewed funding. In the last grant period, members ofthe HDMP published 260 manuscripts, of which 34.6% represent interprogrammatic and 13.1% resulted from intra-programmatic collaborations.
The goal of the Hematopoietic Development &Malignancy Program is to improve the diagnosis and treatment of blood cancers, including leukemia, multiple myeloma, and lymphoma through clinical application of advances in basic research.
|Engle, E K; Fisher, D A C; Miller, C A et al. (2015) Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia. Leukemia 29:869-76|
|Zihni, Ahmed M; Cavallo, Jaime A; Thompson Jr, Dominic M et al. (2015) Evaluation of absorbable mesh fixation devices at various deployment angles. Surg Endosc 29:1605-13|
|Rosenbaum, Joan L; Smith, Joan R; Yan, Yan et al. (2015) Impact of a Neonatal-Bereavement-Support DVD on Parental Grief: A Randomized Controlled Trial. Death Stud 39:191-200|
|Solga, Anne C; Pong, Winnie W; Walker, Jason et al. (2015) RNA-sequencing reveals oligodendrocyte and neuronal transcripts in microglia relevant to central nervous system disease. Glia 63:531-48|
|Yamada, Tomoko; Yang, Yue; Hemberg, Martin et al. (2014) Promoter decommissioning by the NuRD chromatin remodeling complex triggers synaptic connectivity in the mammalian brain. Neuron 83:122-34|
|Lewis Jr, James S; Ali, Sahirzeeshan; Luo, Jingqin et al. (2014) A quantitative histomorphometric classifier (QuHbIC) identifies aggressive versus indolent p16-positive oropharyngeal squamous cell carcinoma. Am J Surg Pathol 38:128-37|
|Griffey, Richard T; Jeffe, Donna B; Bailey, Thomas (2014) Emergency physicians' attitudes and preferences regarding computed tomography, radiation exposure, and imaging decision support. Acad Emerg Med 21:768-77|
|Jorns, Julie M; Thomas, Dafydd G; Healy, Patrick N et al. (2014) Estrogen receptor expression is high but is of lower intensity in tubular carcinoma than in well-differentiated invasive ductal carcinoma. Arch Pathol Lab Med 138:1507-13|
|Jeffe, Donna B; Andriole, Dorothy A; Wathington, Heather D et al. (2014) Educational outcomes for students enrolled in MD-PhD programs at medical school matriculation, 1995-2000: a national cohort study. Acad Med 89:84-93|
|Tait, Sarah; Pacheco, Jose M; Gao, Feng et al. (2014) Body mass index, diabetes, and triple-negative breast cancer prognosis. Breast Cancer Res Treat 146:189-97|
Showing the most recent 10 out of 514 publications